Birlasoft Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/86w0aasmhvkkwp6kwsn9ktct.pdf

Key Takeaways


The Quarter: Growth, Margins & the Invacare Overhang

Guha: "I don't want to kind of be penny wise and pound foolish. I want to invest in the business because we are here to create a business for the next decade."

The $271 Mn Deal Win & Pipeline

Guha: "Do we have more $100 million deals in the pipeline? Well, yes, we do have $100 million deals in the pipeline. Will it close in our favor or whether it will close in the next couple of quarters? Again, very hard for me to say... it is a manifestation of what the client wants to do."

Vertical & Service-Line Performance

Vertical / Service LineTrendCommentary
BFSI▲ StrongGrew 5.3% QoQ; company is investing and very bullish, though Q3 will see furlough impact.
Manufacturing▲ StrongGrew 4.2% QoQ; a key growth driver alongside BFSI.
Healthcare / Life Sciences▼ SoftSoftness expected to bounce back; company is investing for a turnaround and margin improvement.
Energy & Utilities▼ SoftSoftness described as an industry trend; management cannot predict when it will turn around.
Digital & Cloud▲ StrongStrong sequential and YoY growth; Microsoft business is a large, solidly growing component. Data & Analytics showing signs of revival.
ERP▬ Bottoming outAdjusted for Invacare, grew ~1% QoQ and has "bottomed out." Bullishness driven by the SAP S/4HANA 2027 migration deadline, JDE capability, and the mid-tier manufacturing segment in North America.
Infrastructure▬ SteadyGrowing at company average when adjusted for Invacare.

The New Operating Model: Leadership, Incentives & Structure


Gen AI, Capability & the Acquisition Question

Guha: "We will never acquire a company for revenue aggregation or revenue growth, but that has to give us solid capability around the two domains or the two service lines that I spoke about."

People & Utilization


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin exit rateExit Q4 at 16% EBITDAQ4 FY24
Medium-term EBITDA range15.5% to 16.5%, possibly up to 17%, with 1–2% reinvestedNext 1–1.5 years
Q3 performanceMuted due to shorter quarter and furloughs; Q4 back to execution-led performanceQ3 FY24 / Q4 FY24
Large deal revenue rampRevenue uptake from the $100 mn+ deal beginsApril onwards
TCV ambitionExit FY24 with higher total TCV than FY23FY24 exit
Acquisition timelineNo acquisition for a couple more quarters; then only strategic, capability-focused dealsNext 4–6 quarters
Furlough severityNot seeing extended furlough requests; will be in the typical range, though higher than last year because BFSI is growingQ3 FY24
HeadcountPositive headcount addition for FY24FY24

Key Metrics

MetricQ2 FY24
Revenue (reported currency)$158.3 million, +3% QoQ
Revenue (constant currency)₹15.91 crore, +3.1% QoQ
Revenue (INR)₹1,309.9 crore, +10% YoY
Revenue growth ex-Invacare+4.4% QoQ and +13% YoY, excluding the one-time disengagement fee in Q1
EBITDA margin15.8%, +50 bps QoQ; wage hikes of ~90 bps impact absorbed
EBITDA$25 million, up from $23.5 million in Q1
PAT margin11.1%, PAT of $17.5 million
Effective tax rate (full year expected)~25%
Large-deal TCV signed$271 million, including one deal with TCV upwards of $100 million from a Fortune 500 client
TCV growth (past 9 months vs preceding 9 months)+21%
BFSI vertical growth+5.3% QoQ
Manufacturing vertical growth+4.2% QoQ
UtilizationAbove 86%
DSO days52 days
Cash and bank balances$173.5 million, increased by $13.5 million QoQ
Operating cash flow to EBITDA~93%
Active client count278, reduced from 285
Americas revenue share85% to 86% of overall revenues
Interim dividend₹2.50 per share, record date 8 November 2023